{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:00:55Z","timestamp":1787029255880,"version":"build-2736575974"},"reference-count":42,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a type 2 pattern of inflammation resulting in the production of some cytokines. Dupilumab radically changes the treatment of CRSwNP, but, considering its recent approval, it may be useful to evaluate its safety profile in a real-world setting. This work aimed to prospectively highlight the effectiveness and safety profile of dupilumab in patients with CRSwNP enrolled in the Otorhinolaryngology Unit of the University Hospital of Messina. An observational cohort study was carried out considering all patients treated with dupilumab. A descriptive analysis was conducted reporting all demographic characteristics, endoscopic evaluations, and symptom conditions. A total of 66 patients were treated with dupilumab, but three patients were excluded due to a lack of adherence during the observational period. A statistically significant reduction in the Sino-Nasal Outcome Test 22 (SNOT-22) and nasal polyps score (NPS) was shown at the 6th and 12th months compared to baseline values (SNOT-22, \u221237 and \u221250, p &lt; 0.001 for both comparisons; NPS, \u22123 and \u22124, p &lt; 0.001 for both comparisons). During the follow-up, eight patients (12.7%) had a reaction at the site of injection, and seven (11.1%) had transient hypereosinophilia. Given the optimal treatment response and the minimal adverse effects observed, clinicians should consider dupilumab a safe and effective treatment. Further studies are necessary to better understand the long-term effects.<\/jats:p>","DOI":"10.3390\/ph16040630","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:48:11Z","timestamp":1682052491000},"page":"630","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-4596","authenticated-orcid":false,"given":"Cosimo","family":"Galletti","sequence":"first","affiliation":[{"name":"Department of Adult and Developmental Human Pathology \u201cGaetano Barresi\u201d, University of Messina, 98100 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-4696","authenticated-orcid":false,"given":"Maria Antonietta","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5115-6027","authenticated-orcid":false,"given":"Francesco","family":"Ciodaro","sequence":"additional","affiliation":[{"name":"Department of Adult and Developmental Human Pathology \u201cGaetano Barresi\u201d, University of Messina, 98100 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5664-7493","authenticated-orcid":false,"given":"Francesco","family":"Freni","sequence":"additional","affiliation":[{"name":"Department of Adult and Developmental Human Pathology \u201cGaetano Barresi\u201d, University of Messina, 98100 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Galletti","sequence":"additional","affiliation":[{"name":"Department of Adult and Developmental Human Pathology \u201cGaetano Barresi\u201d, University of Messina, 98100 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-7449","authenticated-orcid":false,"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Galletti","sequence":"additional","affiliation":[{"name":"Department of Adult and Developmental Human Pathology \u201cGaetano Barresi\u201d, University of Messina, 98100 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40265-020-01298-9","article-title":"Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ottaviano, G., Saccardo, T., Roccuzzo, G., Bernardi, R., Di Chicco, A., Pendolino, A.L., Scarpa, B., Mairani, E., and Nicolai, P. (2022). Effectiveness of Dupilumab in the Treatment of Patients with Uncontrolled Severe CRSwNP: A \u201cReal-Life\u201d Observational Study in Na\u00efve and Post-Surgical Patients. J. Pers. Med., 12.","DOI":"10.3390\/jpm12091526"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"De Corso, E., Montuori, C., Settimi, S., Mele, D.A., Cantiani, A., Corb\u00f2, M., Cantone, E., Paludetti, G., and Galli, J. (2022). Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP. J. Clin. Med., 11.","DOI":"10.3390\/jcm11040926"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/TCRM.S210648","article-title":"Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date","volume":"16","author":"Kim","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinol. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.5114\/ada.2020.99365","article-title":"Recorded prevalence of nasal polyps increases with age","volume":"38","author":"Raciborski","year":"2021","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_8","first-page":"140","article-title":"Surgical versus medical treatment of nasal polyps","volume":"105","author":"Lildholdt","year":"1989","journal-title":"Rhinology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.otohns.2007.02.004","article-title":"The Lund-Mackay staging system for chronic rhinosinusitis: How is it used and what does it predict?","volume":"137","author":"Hopkins","year":"2007","journal-title":"Otolaryngol. Neck Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0194-5998(97)70005-6","article-title":"Staging for Rhinosinusitis","volume":"117","author":"Lund","year":"1997","journal-title":"Otolaryngol. Neck Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mpdhp.2010.03.008","article-title":"Inflammatory diseases of the nasal cavities and paranasal sinuses","volume":"16","author":"Helliwell","year":"2010","journal-title":"Diagn. Histopathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/lary.24154","article-title":"Subclassification of chronic rhinosinusitis with nasal polyp based on eosinophil and neutrophil","volume":"123","author":"Ikeda","year":"2013","journal-title":"Laryngoscope"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaip.2016.05.004","article-title":"Phenotypes and Emerging Endotypes of Chronic Rhinosinusitis","volume":"4","author":"Bachert","year":"2016","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"572749","DOI":"10.3389\/fcell.2020.572749","article-title":"Interleukin-13 Alters Tight Junction Proteins Expression Thereby Compromising Barrier Function and Dampens Rhinovirus Induced Immune Responses in Nasal Epithelium","volume":"8","author":"Huang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/all.15074","article-title":"Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches","volume":"77","author":"Kato","year":"2022","journal-title":"Allergy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MOO.0000000000000503","article-title":"Endotypes of chronic rhinosinusitis","volume":"27","author":"Yip","year":"2019","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2147\/DDDT.S243053","article-title":"Dupilumab: Clinical Efficacy of Blocking IL-4\/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps","volume":"14","author":"Kariyawasam","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2147\/JAA.S258438","article-title":"Management of Chronic Rhinosinusitis with Nasal Polyposis in the Era of Biologics","volume":"14","author":"Morse","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e15120","DOI":"10.1111\/dth.15120","article-title":"Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis","volume":"34","author":"Napolitano","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_24","unstructured":"(2023, March 01). European Medicines Agency Dupixent\u00ae, Summary of Product Characteristics. Available online: https:\/\/ec.europa.eu\/health\/documents\/communityregister\/2019\/20190506144541\/anx_144541_en.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/1945892419858582","article-title":"Relationship Between Nasal Cycle, Nasal Symptoms and Nasal Cytology","volume":"33","author":"Pendolino","year":"2019","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40463-022-00570-0","article-title":"Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps","volume":"51","author":"Kilty","year":"2022","journal-title":"J. Otolaryngol.\u2014Head Neck Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13223-023-00782-7","article-title":"Clinical outcomes of dupilumab therapy in chronic rhinosinusitis with nasal polyps in a Canadian tertiary care rhinology practice","volume":"19","author":"Grose","year":"2023","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/lary.22461","article-title":"When FESS fails: The inflammatory load hypothesis in refractory chronic rhinosinusitis","volume":"122","author":"Bassiouni","year":"2012","journal-title":"Laryngoscope"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00405-022-07679-y","article-title":"Dupilumab (Dupixent\u00ae) tends to be an effective therapy for uncontrolled severe chronic rhinosinusitis with nasal polyps: Real data of a single-centered, retrospective single-arm longitudinal study from a university hospital in Germany","volume":"280","author":"Jansen","year":"2023","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of Dupilumab on Blood Eosinophil Counts in Patients with Asthma, Chronic Rhinosinusitis with Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103615","DOI":"10.1016\/j.amjoto.2022.103615","article-title":"Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review","volume":"43","author":"Aldajani","year":"2022","journal-title":"Am. J. Otolaryngol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.20138","article-title":"Dupilumab-associated arthralgia: An observational retrospective study in VigiBase\u00ae","volume":"185","author":"Dolladille","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.14639\/0392-100X-N1911","article-title":"Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review","volume":"42","author":"Nitro","year":"2022","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/1346-8138.16595","article-title":"Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis","volume":"50","author":"Chromy","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Barbieri, M.A., Cicala, G., Cutroneo, P.M., Gerratana, E., Palleria, C., De Sarro, C., Vero, A., Iannone, L., Manti, A., and Russo, E. (2020). Safety profile of biologics used in rheumatology: An italian prospective pharmacovigilance study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041227"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Barbieri, M.A., Viola, A., Cicala, G., Spina, E., and Fries, W. (2022). Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123280"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/03007995.2020.1786681","article-title":"Safety profiles of biologic agents for inflammatory bowel diseases: A prospective pharmacovigilance study in Southern Italy","volume":"36","author":"Roberti","year":"2020","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/630\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:20:30Z","timestamp":1760124030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ph16040630"],"URL":"https:\/\/doi.org\/10.3390\/ph16040630","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]}}}